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Background/Aim: The objective of this study was to investigate the effects that the application of mesenchymal stem cells (MSCs) and
platelet-rich plasma (PRP) following tendon repair have on the strength and healing of the tendon and also to examine the possible
mechanisms of action that take place.
Materials and methods: The Achilles tendons of 80 rats were repaired and divided into eight groups. Following the repairs, MSCs
obtained from humans were injected into the rat tendons in groups 1 and 2, a combination of MSCs from humans and PRP from rats
was injected into the tendons in groups 3 and 4, and PRP from rats was injected into the tendons in groups 5 and 6. These procedures all
took place simultaneously. Groups 7 and 8 did not receive any injections following the repairs. The rats were sacrificed at the end of the
first and second months following the procedures, and biomechanical and histopathological analyses were performed.
Results: Inflammatory cell density increased most significantly in the combined group when compared to the first and second months.
The fibroblast density on the tendon repair region was significantly lower in the second-months groups of each intervention compared
to their first-month groups (p = 0.001). For the analysis of the maximum tensile breaking force, the behaviors of the groups over time
were significant when compared to the control groups (p = 0.0015). Also, the mean maximum breaking force in the combined group
was statistically significantly higher at the end of the second month than at the end of the first month (p = 0.0008).
Conclusion: The combination therapy increased tendon strength force. This combination therapy can make a positive contribution to
the healing of tendons after surgery.
Key words: Experimental study, mesenchymal stem cell, platelet-rich plasma, tendon healing

1. Introduction
Recently, biological treatments have been explored with
regard to tendon healing, to speed up healing and increase
the tension of the tendon. On the basis of the hypothesis
proposed in our study, if tendon healing can be accelerated,
adhesions can be prevented by starting tension movements
earlier [1].
Treatment that is based on mesenchymal stem cells
(MSCs) positively affects tissue healing through three
different mechanisms [2]. First, MSCs modulate the
immune response and provide these immunomodulatory
effects through direct cell-to-cell interaction or soluble
immunosuppressive factors [3]. Second, MSCs release

various cytokines, growth factors, and chemokines. These
exert their effects by inhibiting apoptosis and promoting
adjacent cell proliferation [4]. Third, MSCs may have the
potential to differentiate into various cells, some of which
include bone, cartilage, tendon, adipose, bone marrow
stroma, and muscle cells [5].
Platelet-rich plasma (PRP) is a plasma component
obtained with full blood centrifugation, which includes a
higher concentration of platelets than full blood [6,7]. This
plasma has numerous growth factors, enabling the use of
PRP injections in the treatment of various musculoskeletal
diseases. It has been reported that growth factors that are
considered to affect the healing process might, because of
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their effects in increasing tendon regeneration, be able to
be used in the treatment by giving direct local injections to
the lesion sites [8]. There are studies in the literature that
show the positive effects that PRP and mesenchymal stem
cell injections have on tendon healing [9]. However, there
have been no controlled experimental studies that have
demonstrated and compared these effects [10].
The aim of this study was to reveal, separately, the
effects of PRP, MSCs, and therapies that combine MSCs
and PRP on the healing of the Achilles tendons of the rats
used in the experiment and to compare them through
evaluations during the follow-up period.
2. Materials and methods
The approval of Necmettin Erbakan University KONÜDAM
Experimental Medicine Application and Research Center
was obtained for this study (decision number: 2017-D20).
This experimental animal investigation was carried out
according to a high ethical standard.
In our study, rats of the Wistar Albino breed, the
average weight of 350-500 g, the mean age of 8-12 months,
and the male gender were used. A total of 85 rats were
used in the study with five being used only as donors, and
the rats were randomly divided into eight groups using a
closed envelope method with 10 rats in each group. Before
surgery, 30 mg/kg cefazolin sodium (İespor®, İ.E. Ulagay,
Turkey) was administered intraperitoneally to the rats.
Then 35 mg of ketamine HCL (Ketalar®, Pfizer, USA) and
5 mg of xylazine (Rompun®, Bayer, Germany) per kg were
administered intraperitoneally and general anesthesia was
provided. The left tendons of the rats in all the groups
were cut during the same session and repaired using the
modified Kessler method [1]. After the repairs, 0.1 cc of
MSCs obtained from humans was injected in groups 1 and

2 (the recovery of the stem cells was performed according
to the use of human-derived MSCs in the rat tendon
injury model described by Lee et al., stem cell extraction is
further detailed below), a combination of 0.1 cc of MSCs
from humans plus 0.1 cc of PRP obtained from the rats
was injected in groups 3 and 4, and 0.1 cc of PRP from
rats was injected in groups 5 and 6. These injections were
performed simultaneously into the repaired Achilles
tendons of the rats. The rats in two other groups, 7 and 8,
did not receive any injections following surgery, and these
groups were used as controls (Figure 1).
The rats in groups 1, 3, 5, and 7 were sacrificed at the
end of the first month, and the rats in groups 2, 4, 6, and 8 at
the end of the second month. A piece of bone was removed
from the calcaneus and a piece of muscle from the triceps
surae in all groups during tendon excision. Biomechanical
and histopathological analyses were performed on the left
Achilles tendons.
Based on the principle that there is no biomechanical
difference between fresh frozen tendons and never waited
tendons, the tendons obtained from groups 1, 3, 5, and 7
were stored in the laboratory setting at -23 °C until the
biomechanical analysis was performed [11].
2.1. Stem cell preparation
Rats are not preferred as a source of stem cells, since rats
do not have enough stem cell sources and the aim of the
study was to obtain many stem cells. The recovery of the
stem cells was performed according to the use of humanderived MSCs in the rat tendon injury model described
by Lee et al. [12]. The lipoaspirate for the isolation of the
MSCs was obtained from the subcutaneous tissues of
people who had been informed about the subject, had given
consent, and had no health problems; the procedures were
performed in an operating room setting. The lipoaspiratee

Figure 1. The view of the methods for all groups. After the repair procedure, 0.1 cc MSCs were injected in Groups
1 and 2; a combination of 0.1 cc MSCs and 0.1 cc PRP were injected in Groups 3 and 4; 0.1 cc PRP were injected
in Groups 5 and 6; simultaneously. Group 7 and 8 did not receive any injection following surgical stress as control
groups.
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was irrigated witphosphate-buffereded saline, 1% bovine
serum albumin, and 0.025% collagenase type 1, and
the isolated stromal vascular fraction were used in the
study. The MSCs were evaluated in terms of appearance,
viability, and potent. This evaluation involved examining
cellular morphology, doubling times, karyotypes, cell
surface markers (CD44, CD90, CD105, and CD45), and
biological functions such as the growth factor releases and
immunosuppressive activities. The cells that showed less
than 80% viability and less than 1% CD45 positivity were
excluded from the study (Figure 2).
2.2. PRP preparation
Before surgery, 30 mg/kg cefazolin sodium (İespor®, İ.E.
Ulagay, Turkey) was administered intraperitoneally to the
rats. Then 35 mg of ketamine HCL (Ketalar®, Pfizer, USA)
and 5 mg of xylazine (Rompun®, Bayer, Germany) per kg
was administered intraperitoneally and general anesthesia
was provided. For harvesting the PRP, 5 cc of intracardiac
blood was drawn from five donor rats under general
anesthesia. The PRP was obtained using Smith and Nephew
Prosys (PRP) biokits (Smith and Nephew, England) and
table type VS-5000i2 centrifugation devices (Nüve, Turkey)
at 3000 rpm for three 6 min. Platelet measurements were
made in the PRP using a biochemical analysis device
(Siemens Adviva 212i, Germany).
2.3. Histopathological evaluation
The examination was carried out by two different
pathologists. The excised tissues were fixed in 10%
formaldehyde for evaluation under a light microscope.

Sections of 4–5 μm were taken from the samples and
embedded in paraffin blocks for hematoxylin and eosin
(H&E), masson trichrome (MTC), and Alcian blue staining.
In light microscopy, the inflammatory cell density, type of
inflammatory cells, and vascularization were evaluated
in the H&E stained slides, and the fibroblast density was
assessed in the MTC stained slides.
Inflammation and fibrosis scoring methods: 0 = none, 1
= low, 2 = moderate, 3 = high.
Vascularization (at 1 large magnification): 0-5
capillaries = low – 1, 6-10 capillaries = moderate – 2, more
than 10 capillaries = high – 3.
2.4. Biomechanical tests
Biomechanical tests were performed in the Biomechanics
Laboratory. Tendon tensile movements (modulus of
elasticity, stiffness, energy absorption capabilities,
maximum loading amount, breaking loads) were examined.
The maximum tensile strength of the tendons was recorded
in Newtons. Before the tests were done, the tendons were
waited to solve at room temperature and moistened with
ringer lactate solution intermittently to prevent drying [11].
The tests were performed with a tensile device (Autograph
AG-IS 100 kN Shimadzu Co. Kyoto, Japan) by giving a
tensile load at a rate of 1 mm/min. The tensile movements
of the tendons were examined. All breakages at the end of
the tests occurred in the regions that had been cut and then
repaired and in Achilles tendons that had been inserted
into the device from the musculotendinous junction in the
proximal region and the calcaneus in the distal region.

Figure 2. Flowcytometry image of the behavior of CD marker marked mesenchymal stem cells in P blocks, immunophenotyping
of mesenchymal stem cells by flowcytometry. Apoptotic effects on the cells. Upper left is for CD105, upper right is for CD44,
lower left is for CD45, lower right is for CD90.
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2.5. Statistical analysis
Variables were analyzed with ANOVA-type statistic.
Numerical variables are given as a mean (standard
deviation), and categorical variables are presented as
numbers (percentages). Ordinal categorical variables
were analyzed using the R 3.4.3 nparLD package and
dichotomous variables were analyzed using a generalized
linear model. The analyses were performed with R 3.4.3
software for the ordinal variables and SAS University
Edition 9.4 software (SAS, USA) for the ordinal variables
[13]. The results were evaluated at a 95% confidence
interval and p < 0.05 level of significance (Figure 3).
3. Results
3.1. Histopathological findings
Inflammatory cell density were analyzed as low–moderate–
high (Figure 4a–4c), vascularization was analyzed as low–
moderate–high (Figure 4d–4f), and fibroblast density was
analyzed as low–moderate–high (Figure 4g–4i) in the
histopathological findings (Figure 4).
3.1.1. Inflammatory cell density
At the end of the first month, the inflammatory cell
density was low in 40%, moderate in 40%, and high in 20%

Figure 3. Hypothetical reviews of tendon analyzes.
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of the rats in group 1 (MSCs), low in 20%, moderate in
40%, and high in 40% of the rats in group 3 (combined).
The inflammatory cell density was moderate in 60% and
high in 40% of the rats in group 5 (PRP). However, the
inflammatory cell density was high in all of the rats in the
control group.
At the end of the second month, the inflammatory cell
density was low in 40%, moderate in 20%, and high in 40%
of the tissues in group 2 (MSCs) and was high in all tissues
in group 4 (combined). The inflammatory cell density was
low in 20%, moderate in 40%, and high in 40% of the tissues
in group 6 (PRP) and low in 20%, moderate in 60%, and
high in 20% of the tissues in group 8 (control) (Table 1).
In the analysis of the inflammatory cell density, the
group-time interaction was significant in all groups (p =
0.038). However, the changes in inflammatory cell densities
over time were different among the groups (Figure 5).
3.1.2. Vascularization
At the end of the first month, the vascularization was low
in 20%, moderate in 60%, and high in 20% of the tissues
in group 1 (MSCs), while it was moderate in 20% and
high in 80% of the tissues in group 3 (combined). The
vascularization was moderate in 40% and high in 60% of

UYAR et al. / Turk J Med Sci

Figure 4. Histopathologic images. a-b-c: Inflammation low-moderate-high (x100,100,200 H&E) d-e-f: Vascularization
low-moderate-high (x40,200,200 H&E) g-h-i: Fibroblast increase low-moderate-high (x100 Masson’s Trichrome)
Table 1. Inflammatory cell density in groups.
Inflammatory cell density
Groups

Month 1
Low

MSCs

Month 2
Moderate High

Low

Moderate

High

4 (%40) 4 (%40)

2 (%20)

4 (%40)

2 (%20)

4 (%40)

Combined 2 (%20) 4 (%40)

4 (%40)

0 (%0)

0 (%0)

10 (%100)

PRP

0 (%0)

6 (%60)

4 (%40)

2 (%20)

4 (%40)

4 (%40)

Control

0 (%0)

0 (%0)

10 (%100) 2 (%20)

6 (%60)

2 (%20)

the tissues in group 5 (PRP) and was low in 20%, moderate
in 40%, and high in 40% of the tissues in group 7 (control).
At the end of the second month, the vascularization was
moderate in 60% and high in 40% of the tissues in group
2 (MSCs), while it was moderate in 20% and high in 80%
of the tissues in group 4 (combined). The vascularization
was low in 20%, moderate in 40%, and high in 40% of the
tissues in group 6 (PRP) and was low in 20%, moderate in
60%, and high in 20% of the tissues in group 8 (control)
(Table 2).

Group

Month

Group-time
interaction

ANOVA-type
statistic: 2.17
Df: 2.79
P: 0.09

ANOVA-type
statistic: 0.01
Df: 1
P: 0.91

ANOVA-type
statistic: 3.03
Df: 2.48
P: 0.038

In the analysis of the vascularization, the group-time
interaction was not significant in any of the groups (p =
0.49). The group and time effects were also not significant
(p = 0.13 and p = 0.76, respectively), and the levels of
vascularization remained the same over time in all the
groups (Figure 6).
3.1.3. Fibroblast density
At the end of the first month, the fibroblast density was low
in 20%, moderate in 20%, and high in 60% of the tissues
in group 1 (MSCs), while it was low in 20%, moderate in
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Figure 5. Inflammatory cell density group-time plot of the groups. The inflammatory cell density was highest
in the control group at the end of the first month, but was lowest in that group at the end of the second month,
while being higher in all other groups. Inflammatory cell density increased most significantly in the combined
group when compared at the first and second months.
Table 2. Vascularization in groups.
Vascularization
Groups

Month 1

Month 2

Low

Moderate

High

Low

Moderate

High

MSCs

2 (%20)

6 (%60)

2 (%20)

0 (%0)

6 (%60)

4 (%40)

Combined

0 (%0)

2 (%20)

8 (%80)

0 (%0)

2 (%20)

8 (%80)

PRP

0 (%0)

4 (%40)

6 (%60)

2 (%20)

4 (%40)

4 (%40)

Control

2 (%20)

4 (%40)

4 (%40)

2 (%20)

6 (%60)

2 (%20)

40%, and high in 40% of the tissues in group 3 (combined).
For the tissues in group 5 (PRP), the fibroblast density was
moderate in 80% and high in 20%, and the fibroblast and
collagen densities were moderate in 20% and high in 80%
of the tissues in group 7 (control).
At the end of the second month, the fibroblast density
was low in 20%, moderate in 60%, and high in 20% of the
tissues in group 2 (MSCs), while it was moderate in 80%
and high in 20% of the tissues in group 4 (combined). For
the tissues in group 6 (PRP), the fibroblast density was low
in 20% and moderate in 80%, and it was low in 60% and
moderate in 40% of the tissues in group 8 (control) (Table
3).
In the fibrosis analysis, the group*time interaction was
significant (p = 0.06). The changes in cell densities of the
groups over time were not different from each other. The
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Group

Month

Group-time
interaction

ANOVA-type
statistic: 1.96
Df: 2.64
P: 0.12

ANOVA-type
statistic: 0.09
Df: 1
P: 0.75

ANOVA-type
statistic: 0.74
Df: 2.23
P: 0.49

time effect was significant (p = 0.001). Fibrosis values of
the groups were not different from each other (p = 0.79)
(Figure 7).
3.2. Biomechanical findings
In the maximum breaking force analysis, the behaviors
of all groups over time were statistically significant when
compared to the control group (p = 0.0015) (Figure 8).
The mean maximum breaking force of the tendons was
found to be 223.51 in group 1, 410.90 in group 2, 248.96
in group 3, 623.69 in group 4, 418.40 in group 5, 341.86
in group 6, 358.26 in group 7, and 160.55 in group 8. The
standard deviation was calculated as 71.8196 in all groups
(Table 4).
A comparison of the changes between the groups
in terms of the mean maximum breaking force of the
tendons, according to months, found that this figure was

UYAR et al. / Turk J Med Sci

Figure 6. Vascularization group-time plot of the groups. The vascularization decreased in the control and PRP
groups but increased at the end of the second month in the group that received MSCs obtained from humans.
In the combined group, the vascularization level was the highest after the first month and did not change at
the end of the second month.
Table 3. Fibroblast density in groups.
Fibroblast density
Groups

Month 1

Month 2

Low

Moderate

High

Low

Moderate

MSCs

2 (%20)

2 (%20)

6 (%60)

2 (%20) 6 (%60)

2 (%20)

Combined

2 (%20)

4 (%40)

4 (%40)

0 (%0)

2 (%20)

PRP

0 (%0)

8 (%80)

2 (%20)

2 (%20) 8 (%80)

0 (%0)

Control

0 (%0)

2 (%20)

8 (%80)

6 (%60) 4 (%40)

0 (%0)

8 (%80)

lower in group 1 than in group 2, but the difference was
not statistically significant (p = 0.07). However, the mean
maximum breaking force was lower in group 3 than in
group 4, and this difference was statistically significant
(p = 0.0008). The mean maximum breaking force was
higher in group 5 than in group 6 (p=0.46), and the mean
maximum breaking force was higher in group 7 than in
group 8, but neither of these differences was statistically
significant (p = 0.06).
The mean maximum breaking force of the tendons,
according to months, in all groups was also compared to
the control group. At the end of the first month, the mean
maximum breaking force was lower in group 1 than in
group 7, but the difference was not statistically significant
(p = 0.19). The mean maximum breaking force was also
lower in group 3 than in group 7, and the difference was
not statistically significant (p = 0.28). While the mean

Group

Month

ANOVA-type
statistic: 0.24
Df: 2.06
P: 0.79

ANOVA-type
statistic: 10.3
Df: 1
P: 0.001

Group- time
interaction

High
ANOVA-type
statistic: 2.78
Df: 1.99
P: 0.06

maximum breaking force was higher in group 5 than in
group 7, this difference was not statistically significant (p
= 0.55) either.
At the end of the second month, the mean maximum
breaking force was higher in group 2 than in group 8,
and this difference was statistically significant (p = 0.01).
In addition, at the end of the second month, the mean
maximum breaking force was higher in group 4 than
in group 8, and again the difference was statistically
significant (p < 0.0001). However, at the end of the second
month, although the mean maximum breaking force was
higher in group 6 than in group 8, the difference was not
statistically significant (p = 0.08).
4. Discussion
After tendon repairs have been completed, extrinsic and
intrinsic healing is observed and a number of different
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Figure 7. Fibroblast density-time plot of the groups. Fibroblast density levels decreased from the first month and
toward the second month in all groups. This decrease was slower in the combined group than in the other groups.

Figure 8. Maximum breaking force plot of the groups. The mean maximum breaking force in the combined group was
statistically significantly higher at the end of the second month than at the end of the first month. The mean maximum
breaking force in the MSC group was higher at the end of the second month than at the end of the first month. The mean
tendon forces that were measured in the control and PRP groups at the end of the first month were higher than the mean forces
measured at the end of the second month.
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Table 4. The mean maximum breaking force and standard deviation of the groups.

Groups

The mean maximum breaking force

Df

t value

P

410.90 ± 120.98

32

-1.84

0.07

248.96 ± 167.06

623.69 ± 157.42

32

-3.69

0.0008

418.40 ± 164.58

341.86 ± 213.57

32

0.75

0.46

358.26 ± 220.50

160.55 ± 127.05

32

1.95

0.06

Month 1

Month 2

MSCs

223.51 ± 39.22

Combined
PRP
Control

treatment methods have recently been investigated to
achieve a balance between the two types of healing [1418].
According to the literature, inflammatory cells and
high amounts of fibrosis have been found around the
suture material in the early period after tendons are
repaired [19,20].
Cell migration occurs as part of the inflammatory
process of tendon healing. Growth factors and cytokines
also stimulate fibroblasts, and the cell/matrix ratio is
regulated by the new collagen fibers that are formed.
During the later period after tendon repairs, the numbers
of cells decrease, and apoptosis is one possible reason for
this decrease [19,20]. In our study, the inflammatory cell
density was highest in the control group at the end of the
first month, but was lowest in that group at the end of the
second month, while being higher in all other groups.
Inflammatory cell density increased most significantly in
the combined group when compared to the first and second
months. With regard to the analysis of the inflammatory
cell density, the group-time interaction was significant (p =
0.038), and the changes in the inflammatory cell densities
over time were different among the groups. The reason for
the rapid decrease in the inflammatory cells in the control
group is that the apoptosis process occurs more quickly in
this group. The increase that occurred in the inflammatory
cells in the combined group toward the end of the second
month when compared to that of the other groups may
cause the density of fibroblasts to be higher in this region.
This positive contribution may, then, allow the maximum
breaking force to reach a higher level in the combined
group than in the others.
In the analysis of the vascularization, the grouptime interaction and the group and time effects were
not statistically significant. However, the vascularization
decreased in the control and PRP groups but increased at
the end of the second month in the group that received
MSCs obtained from humans. In the combined group, the
vascularization level was the highest after the first month
and did not change at the end of the second month. One
of the reasons for the increase in the mean maximum
breaking force in the group that received MSCs obtained

from humans and in the combined group might be this
vascularization pattern.
In our study, fibroblast density levels decreased from
the first month and toward the second month in all groups.
This decrease was slower in the combined group than in
the other groups, and the decrease was very significant in
the control group. The reason for this pattern may be that
the apoptosis process extended over time in the combined
group. In our study, time effect was significant in the
fibroblast density analysis (p = 0.001). We believe that
the pattern of delayed apoptosis in the combined group
keeps the fibroblast density high for a long time, and this
positively contributes to the tension force of the tendon.
Although studies have not found a statistically
significant difference between the control and MSC
groups in terms of biomechanical evaluation, significant
results have been obtained in histologic evaluations [2123]. In our study, in terms of biomechanical evaluations,
the behaviors of the groups over time were different in the
analysis of the maximum breaking force of the tendons,
and the difference was statistically significant (p = 0.0015).
The mean maximum breaking force in the combined
group was statistically significantly higher at the end of
the second month than at the end of the first month (p =
0.0008). In addition, the mean maximum breaking force in
the MSC group was higher at the end of the second month
than at the end of the first month, but this difference was
not statistically significant. The mean tendon forces that
were measured in the control and PRP groups at the end of
the first month were higher than the mean forces measured
at the end of the second month. In our daily observations,
we found that the rats in all groups were more likely to
protect their left legs, on which the surgeries had been
performed, and to hold them in the resting position in
the postoperative period. The reason for the decreased
maximum breaking forces in the tendons at the end of the
second month in the control and PRP groups might be that,
during the healing process, the rats did not put load on the
legs on which the surgeries had been performed. However,
no negative effects were found from this in the MSC and
combined groups, and higher values were measured in
these groups at the end of the second month, with this
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difference being more prominent in the combined group.
We believe that this is due to the synergistic effect of the
combination of MSCs and PRP and maybe because MSCs
tend to have strong effects with regard to growth factors.
In spite of the tendency of the rats to protect the legs on
which the surgeries had been performed, the MSCs and
the combination of MSCs and PRP positively contributed
to healing. Also, this contribution was more prominent in
the combined group.
Uysal et al. conducted a study on the Achilles tendons
of rabbits in 2012, using autologous PRP and PRP+stem
cell combinations, and obtained positive results in terms
of tensile strength in the stem cell group [24]. However, a
disadvantage to this study is that it has no control group
or stem cell group. An important difference between this
study and ours is that the stem cell is heterologous in ours
and includes all groups.
Yuksel et al. used autologous bone marrow stem cells
and autologous PRP on the Achilles tendons of rats in a
study done in 2016, and successful results were obtained
[25]. However, this study has no group in which stem cells
and PRP treatment are combined.
In a study conducted in 2013 by Martinello et al.,
autologous treatments using PRP and MSCs were applied
to the flexor tendons of sheep, and successful results were
obtained [26]. However, although this study includes stem
cells, PRP, and combined groups, there is no control group.
Our study differs from other studies because it contains all
of the following groups and combinations: a control group,
an MSC group, a PRP group, and combined groups (MSCs
+ PRP). In addition, our study is similar to other studies in
terms of the use of autologous PRP but differs from other
studies in terms of the production of stem cells.
Also, MSCs in our study were not obtained from the
rats but from a different species, and no study reporting on
combined treatment using MSCs from a different species is

available in the literature. In addition, having a donor area
and providing more MSCs are important advantages that
result from this method. However, the antigenic structure
of the stem cell negatively affects the survival time in the
application area, and this effect can be considered to be
a disadvantage of the study. Another limitation of the
study is that the future levels of the mesenchymal stem
cell densities in the tissue are unknown, and our study
includes no review for this.
With regard to the study performed by Lee et al., the
xenogenic stem cells that were obtained can maintain their
viability for about four weeks [12]. With the desensitization
studies that will be carried out in the future, we think
that the viability period of xenogenic stem cells might be
extended, and that these stem cells may be useful in future
experimental trials.
5. Conclusion
In conclusion, our study found that at the end of the
second month after the rats’ Achilles tendons had been
repaired, there was a higher mean maximum breaking
force in the group in which the combination of the MSCs
and PRP was used than in any of the other groups. In
addition, this difference was found to be statistically and
histologically significant. Based on this result, we believe
that combination therapy using MSCs and PRP will guide
further clinical studies and influence the tendon repair
process in the future.
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